INO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Inovio Pharmaceuticals Inc

NASDAQ | INO

2.02

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$134.66M

Market Cap

-

P/E Ratio

-2.72

EPS

$4.61

52 Week High

$1.30

52 Week Low

HEALTHCARE

Sector

INO Chart

Recent Chart
Price Action

INO Technicals

Tags:

INO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2.9M
Total Revenue $218K
Cost Of Revenue $3.1M
Costof Goods And Services Sold $3.1M
Operating Income -$112M
Selling General And Administrative $37B
Research And Development $76M
Operating Expenses $111M
Investment Income Net -
Net Interest Income $4.6M
Interest Income $4.8M
Interest Expense $178K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.1M
Income Before Tax -$107M
Income Tax Expense -$107B
Interest And Debt Expense -
Net Income From Continuing Operations -$107M
Comprehensive Income Net Of Tax -
Ebit -$107M
Ebitda -$104M
Net Income -$107M

Revenue & Profitability

Earnings Performance

INO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $113M
Total Current Assets $98M
Cash And Cash Equivalents At Carrying Value $66M
Cash And Short Term Investments $66M
Inventory -
Current Net Receivables $1.2M
Total Non Current Assets $15M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $1.6M
Short Term Investments $28M
Other Current Assets $2.5M
Other Non Current Assets -
Total Liabilities $45M
Total Current Liabilities $35M
Current Accounts Payable $6.4M
Deferred Revenue -
Current Debt -
Short Term Debt $2.5M
Total Non Current Liabilities $9.4M
Capital Lease Obligations $12M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $12M
Other Current Liabilities $26M
Other Non Current Liabilities -
Total Shareholder Equity $69M
Treasury Stock -
Retained Earnings -$1.7B
Common Stock $36K
Common Stock Shares Outstanding $27M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$104M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $3.1M
Capital Expenditures $488K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $104M
Cashflow From Financing $51M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$107M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$2.9M
Total Revenue $218K
Cost Of Revenue $3.1M
Costof Goods And Services Sold $3.1M
Operating Income -$112M
Selling General And Administrative $37B
Research And Development $76M
Operating Expenses $111M
Investment Income Net -
Net Interest Income $4.6M
Interest Income $4.8M
Interest Expense $178K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $3.1M
Income Before Tax -$107M
Income Tax Expense -$107B
Interest And Debt Expense -
Net Income From Continuing Operations -$107M
Comprehensive Income Net Of Tax -
Ebit -$107M
Ebitda -$104M
Net Income -$107M

INO News

INO Profile

Inovio Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Inovio Pharmaceuticals Inc. is a cutting-edge biotechnology company dedicated to developing innovative DNA-based therapeutics aimed at treating a range of diseases, including cancer and infectious diseases such as HPV. Leveraging its proprietary platform, Inovio stands at the forefront of immunotherapy advancements and has cultivated a diverse pipeline of product candidates designed to meet significant unmet medical needs. The firm’s ongoing clinical research initiatives reflect its commitment to innovation and adaptability in the face of evolving health challenges, positioning Inovio for potential growth and long-term value creation in the biopharmaceutical landscape.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
INTC
+2.73%
$36.81
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
WULF
+6.45%
$14.84
RUBI
-8.19%
$0.21
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BAC
+0.97%
$52.99
BIYA
+11.34%
$0.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
AFMD
-34.94%
$0.18
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
BABA
+0.37%
$157.60
SNAP
+0.23%
$7.62
NVTS
+3.86%
$8.34
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
INHD
-7.00%
$0.20
NVO
+3.50%
$48.71
NAKA
+7.20%
$0.49
KDLY
+7.20%
$0.49
ASST
+2.65%
$1.16
JBLU
+3.43%
$4.52
SAND
-6.04%
$12.12
CLSK
+11.96%
$15.05
LEN
+0.15%
$131.28
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
FCX
+2.62%
$42.15
AUR
+3.31%
$4.05
AMC
+1.76%
$2.30
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
SOLT
+7.29%
$8.97
RZLV
-0.99%
$2.98
TSLG
+3.51%
$9.12
KO
+0.37%
$72.88
NEHC
+8.33%
$5.07
VICI
+0.27%
$28.83
GAP
+3.49%
$27.53
CSX
+1.14%
$35.30
DEFT
+20.86%
$1.68
PFSA
+5.19%
$0.16
ZIM
+0.97%
$19.70
ONDS
-3.80%
$7.92
SANA
+14.52%
$4.02
CHR
+3.95%
$0.04
MPW
+2.12%
$5.77
CRCA
+7.60%
$3.68
WFC
+0.54%
$85.56
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
BBWI
+2.78%
$17.37
UPXI
-7.02%
$2.78
CRM
-2.55%
$228.15
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCC
+0.96%
$7.32
CCCS
+0.96%
$7.32
IAG
+5.29%
$15.31
FL
-0.37%
$24.01
INFY
+0.81%
$17.42
HLN
-0.61%
$9.76
DAL
+3.41%
$64.27
UMC
+0.82%
$7.33
CPRT
-0.79%
$38.75
SABR
-1.84%
$1.60
TGT
+3.71%
$89.80
JPM
+1.53%
$307.64
ORC
+0.82%
$7.29
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
BYND
+19.00%
$1.02
ZYXI
+115.62%
$1.59
VINE
+10.76%
$0.39
KTTA
+32.06%
$1.39
BITF
+11.91%
$3.10
PLUG
+1.53%
$1.98
IPG
-1.95%
$24.57
AXDX
-61.36%
$0.03
INTC
+2.73%
$36.81
SPRC
-9.01%
$2.22
ADAP
-15.14%
$0.05
YGMZ
-8.37%
$0.11
WULF
+6.45%
$14.84
RUBI
-8.19%
$0.21
F
+0.15%
$13.19
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
TLRY
-19.39%
$0.83
SRM
+53.27%
$10.30
BAC
+0.97%
$52.99
BIYA
+11.34%
$0.28
TWOH
0.00%
$0.00
ACHR
+1.49%
$7.49
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
T
-0.15%
$25.82
AEHL
+8.43%
$3.47
IREN
+2.06%
$48.45
ITUB
+3.23%
$7.66
NVDA
-1.02%
$178.41
AFMD
-34.94%
$0.18
PLTZ
-2.62%
$7.43
APLD
+5.05%
$24.94
BABA
+0.37%
$157.60
SNAP
+0.23%
$7.62
NVTS
+3.86%
$8.34
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
KWM
+10.50%
$0.72
KSS
+7.49%
$24.10
INHD
-7.00%
$0.20
NVO
+3.50%
$48.71
NAKA
+7.20%
$0.49
KDLY
+7.20%
$0.49
ASST
+2.65%
$1.16
JBLU
+3.43%
$4.52
SAND
-6.04%
$12.12
CLSK
+11.96%
$15.05
LEN
+0.15%
$131.28
SHOT
-74.37%
$0.39
ZAPP
-46.30%
$0.15
NBIS
+6.53%
$94.69
FCX
+2.62%
$42.15
AUR
+3.31%
$4.05
AMC
+1.76%
$2.30
CIFR
+6.60%
$20.41
BMNR
+6.77%
$33.89
SOLT
+7.29%
$8.97
RZLV
-0.99%
$2.98
TSLG
+3.51%
$9.12
KO
+0.37%
$72.88
NEHC
+8.33%
$5.07
VICI
+0.27%
$28.83
GAP
+3.49%
$27.53
CSX
+1.14%
$35.30
DEFT
+20.86%
$1.68
PFSA
+5.19%
$0.16
ZIM
+0.97%
$19.70
ONDS
-3.80%
$7.92
SANA
+14.52%
$4.02
CHR
+3.95%
$0.04
MPW
+2.12%
$5.77
CRCA
+7.60%
$3.68
WFC
+0.54%
$85.56
GOOGL
-0.33%
$318.88
MARA
+6.50%
$11.83
GPUS
+1.14%
$0.33
BBWI
+2.78%
$17.37
UPXI
-7.02%
$2.78
CRM
-2.55%
$228.15
TSLA
+0.65%
$429.38
IBRX
+2.40%
$2.13
CCC
+0.96%
$7.32
CCCS
+0.96%
$7.32
IAG
+5.29%
$15.31
FL
-0.37%
$24.01
INFY
+0.81%
$17.42
HLN
-0.61%
$9.76
DAL
+3.41%
$64.27
UMC
+0.82%
$7.33
CPRT
-0.79%
$38.75
SABR
-1.84%
$1.60
TGT
+3.71%
$89.80
JPM
+1.53%
$307.64
ORC
+0.82%
$7.29
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.